Oncology

Patients with early-stage breast cancer may not need aggressive treatment.

Combination therapy may improve treatment strategies for hepatocellular carcinoma.

Promise seen in targeting protein in PTEN-deficient cancer cells.

Updates on the national performance benchmarks for digital mammography.

Prostate cancer can be subtyped based on cell of origin as luminal A, luminal B, and basal cell subtypes.

Patients with luminal B prostate cancer benefited the most from androgen deprivation therapy.

Treatment shows benefit in patients with low-grade serous cancer.

Early-stage breast cancer patients with low muscle quality and quantity have twice the risk of hospitalization.

Treatment with the myxoma virus reduced tumor burden and led to a modest decrease in disease progression in mice.

Top news of the week in oncology and cancer drug development.

PI3K inhibitors loaded into nanoparticles provided targeted treatment for head and neck cancers.

Recombinant shell nanoparticles could deliver drugs straight to cancer cells.

Sarcopenia identified as an independent risk factor.

African American patients are more likely to be diagnosed with advanced cancer and have higher mortality.

Premenopausal African American women with a p35 mutation may be at a higher risk of developing breast cancer.

Top news of the day from across the health care landscape.

Drug may offer an effective alternative to chemotherapy for patients with leukemia.

Combination treatment helped increase invasive disease-free survival in patients with an aggressive type of early breast cancer.

Analysis confirms the safety and efficacy of palliative radiation therapy for painful bone metastases.

Carcinoid syndrome affects some patients with carcinoid tumors.

Investigational drug treats patients with relapsed or refractory AML with an isocitrate dehydrogenase 2 mutation.

Xermelo plus somatostatin analog therapy approved to treat carcinoid diarrhea syndrome.

Top news of the day from across the health care landscape.

Combination therapy shows promise treating pancreatic cancer.

Nab-paclitaxel prevents proliferation, and increases immune system response to cancer cells.

G-CSF promotes regeneration of sperm cells in cancer patients.

A majority of glioblastomas change their genomic profile during therapy, new research finds.

Targeting the interactions between neurons and cancer cells may be a powerful strategy in future cancer treatments.